On the public citation graph
mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients
0 signed · 85 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2021.3341openalex-snapshot
Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2
inferredcites →https://doi.org/10.1016/j.ccell.2021.06.002openalex-snapshot
Seroconversion rates following COVID-19 vaccination among patients with cancer
inferredcites →https://doi.org/10.1016/j.ccell.2021.07.012openalex-snapshot
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
inferredcites →https://doi.org/10.1016/j.ccell.2021.09.001openalex-snapshot
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies
inferredcites →https://doi.org/10.1016/j.cell.2020.02.052openalex-snapshot
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
inferredcites →https://doi.org/10.1016/s0140-6736(20)32661-1openalex-snapshot
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
inferredcites →https://doi.org/10.1016/s0140-6736(21)00947-8openalex-snapshot
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
inferredcites →https://doi.org/10.1016/s2665-9913(21)00212-5openalex-snapshot
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
inferredcites →https://doi.org/10.1038/s41586-021-03530-2openalex-snapshot
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
inferredcites →https://doi.org/10.1038/s41586-021-03791-xopenalex-snapshot
Systems vaccinology of the BNT162b2 mRNA vaccine in humans
inferredcites →https://doi.org/10.1038/s41587-020-0631-zopenalex-snapshot
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
inferredcites →https://doi.org/10.1038/s41591-021-01386-7openalex-snapshot
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
inferredcites →https://doi.org/10.1038/s41591-021-01507-2openalex-snapshot
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
inferredcites →https://doi.org/10.1038/s43018-021-00191-yopenalex-snapshot
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy
inferredcites →https://doi.org/10.1056/nejmc2101667openalex-snapshot
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
inferredcites →https://doi.org/10.1056/nejmoa2027906openalex-snapshot
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
inferredcites →https://doi.org/10.1056/nejmoa2034201openalex-snapshot
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
inferredcites →https://doi.org/10.1056/nejmoa2034577openalex-snapshot
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
inferredcites →https://doi.org/10.1056/nejmoa2101765openalex-snapshot
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
inferredcites →https://doi.org/10.1093/cid/ciab300openalex-snapshot
Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents
inferredcites →https://doi.org/10.1093/infdis/jiab569openalex-snapshot
Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
inferredcites →https://doi.org/10.1097/mcc.0000000000000907openalex-snapshot
Coronavirus disease 2019 in immunocompromised patients: a comprehensive review of coronavirus disease 2019 in hematopoietic stem cell recipients
inferredcites →https://doi.org/10.1101/2021.01.29.21250653openalex-snapshot
Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine
inferredcites →https://doi.org/10.1126/scitranslmed.abi8961openalex-snapshot
Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals
inferredcites →https://doi.org/10.1128/jcm.01224-20openalex-snapshot
Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively
inferredcites →https://doi.org/10.1128/spectrum.00247-21openalex-snapshot
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
inferredcites →https://doi.org/10.1136/gutjnl-2021-324789openalex-snapshot
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
inferredcites →https://doi.org/10.1158/2159-8290.cd-20-0773openalex-snapshot
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
inferredcites →https://doi.org/10.1158/2643-3230.bcd-21-0139openalex-snapshot
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies
inferredcites →https://doi.org/10.1158/2643-3230.bcd-21-0166openalex-snapshot
How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies
inferredcites →https://doi.org/10.1172/jci149154openalex-snapshot
One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19
inferredcites →https://doi.org/10.1182/blood.2021012443openalex-snapshot
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies
inferredcites →https://doi.org/10.1186/s13578-021-00713-2openalex-snapshot
Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
inferredcites →https://doi.org/10.1371/journal.pone.0257646openalex-snapshot
Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times
inferredcites →https://doi.org/10.1515/cclm-2021-0023openalex-snapshot
Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies
inferredcites →https://doi.org/10.15585/mmwr.mm7037e1openalex-snapshot
Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021
inferredcites →https://doi.org/10.1681/asn.2021040490openalex-snapshot
Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients
inferredcites →https://doi.org/10.2807/1560-7917.es.2021.26.6.2100096openalex-snapshot
Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1007/s40620-022-01371-4openalex-snapshot
Humoral and cellular immune responses to the mRNA-1273 SARS-CoV-2 vaccine booster in patients on maintenance dialysis
inferred← citeshttps://doi.org/10.1016/j.it.2023.01.005openalex-snapshot
COVID-19 vaccines and a perspective on Africa
inferred← citeshttps://doi.org/10.1016/j.jaut.2022.102848openalex-snapshot
Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy
inferred← citeshttps://doi.org/10.1016/j.jtauto.2022.100164openalex-snapshot
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies
inferred← citeshttps://doi.org/10.1016/j.jvacx.2024.100553openalex-snapshot
Kinetics of humoral and cellular immune responses 5 months post-COVID-19 booster dose by immune response groups at the peak immunity phase: An observational historical cohort study using the Fukushima vaccination community survey
inferred← citeshttps://doi.org/10.1016/j.omtm.2023.101110openalex-snapshot
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection
inferred← citeshttps://doi.org/10.1016/j.prp.2023.154310openalex-snapshot
The case of T-ALL presenting with NK phenotype after COVID-19 vaccination
inferred← citeshttps://doi.org/10.1038/s43856-023-00245-5openalex-snapshot
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV
inferred← citeshttps://doi.org/10.1080/21645515.2023.2292376openalex-snapshot
B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients
inferred← citeshttps://doi.org/10.1093/infdis/jiad148openalex-snapshot
Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases
inferred← citeshttps://doi.org/10.1101/2022.07.01.22277132openalex-snapshot
B Cell Response Six Months after SARS-CoV-2 mRNA Vaccination in People Living with HIV Under Antiretroviral Therapy
inferred← citeshttps://doi.org/10.1101/2022.09.21.22280205openalex-snapshot
Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination
inferred← citeshttps://doi.org/10.1136/ard-2022-222682openalex-snapshot
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
inferred← citeshttps://doi.org/10.1159/000528170openalex-snapshot
Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study
inferred← citeshttps://doi.org/10.1182/bloodadvances.2022008445openalex-snapshot
Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination
inferred← citeshttps://doi.org/10.1186/s12916-023-02868-wopenalex-snapshot
Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
inferred← citeshttps://doi.org/10.1186/s12985-024-02410-1openalex-snapshot
Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination
inferred← citeshttps://doi.org/10.15406/jlprr.2023.10.00295openalex-snapshot
Patients under medical conditions, immunogenicity and safety of covid-19 vaccines: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.23880/vij-16000311openalex-snapshot
Monitoring of Immune Response Following Covid-19 Vaccination
inferred← citeshttps://doi.org/10.3122/jabfm.2023.230028r1openalex-snapshot
COVID-19 mRNA Vaccination Trends Among Immunocompromised Patients
inferred← citeshttps://doi.org/10.3389/fcimb.2023.1207313openalex-snapshot
Differential cellular and humoral immune responses in immunocompromised individuals following multiple SARS-CoV-2 vaccinations
inferred← citeshttps://doi.org/10.3389/fimmu.2022.1033770openalex-snapshot
SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1061255openalex-snapshot
Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1087996openalex-snapshot
Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1104124openalex-snapshot
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
inferred← citeshttps://doi.org/10.3389/fimmu.2025.1588259openalex-snapshot
The immunological impact of revaccination in a hybrid-immune world
inferred← citeshttps://doi.org/10.3389/fimmu.2025.1590939openalex-snapshot
Negative associations of age and lifestyle factors with the antibody response to the COVID-19 vaccine BNT162b2 in health workers from Spain
inferred← citeshttps://doi.org/10.3390/medicina58070893openalex-snapshot
Antibody Responses after Two Doses of COVID-19 mRNA Vaccine in Dialysis and Kidney Transplantation Patients Recovered from SARS-CoV-2 Infection
inferred← citeshttps://doi.org/10.3390/pathogens13060506openalex-snapshot
The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study
inferred← citeshttps://doi.org/10.3390/v14122605openalex-snapshot
Antibody Titer Correlates with Omicron Infection in Vaccinated Healthcare Workers
inferred← citeshttps://doi.org/10.3390/vaccines12010069openalex-snapshot
No Waning of Pneumococcal Vaccine Responses over Time in People with Inflammatory Arthritis: Findings from a Single Centre Cohort
inferred← citeshttps://doi.org/10.3390/vaccines12030247openalex-snapshot
Hybrid Immunity Improves the Immune Response after the Fourth COVID-19 Vaccine Dose in Individuals with Medical Conditions Predisposing to Severe COVID-19
inferred← citeshttps://doi.org/10.3899/jrheum.220475openalex-snapshot
B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab
inferred← citeshttps://doi.org/10.4110/in.2023.23.e39openalex-snapshot
COVID-19 Vaccination Alters NK Cell Dynamics and Transiently Reduces HBsAg Titers Among Patients With Chronic Hepatitis B
inferred← citeshttps://doi.org/10.4236/ojneph.2024.141008openalex-snapshot
Humoral Response and Tolerance of Vaccination against SARS-CoV-2 in Adults Senegalese Patients Undergoing Hemodialysis: A Multicenter Prospective Study
inferred← citeshttps://doi.org/10.6084/m9.figshare.26036407openalex-snapshot
Additional file 1 of Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination
inferred← citeshttps://doi.org/10.6084/m9.figshare.26597228openalex-snapshot
Additional file 1 of Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
inferred← citeshttps://doi.org/10.6084/m9.figshare.26597231openalex-snapshot
Additional file 2 of Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
inferred← citeshttps://doi.org/10.6084/m9.figshare.26597234openalex-snapshot
Additional file 3 of Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
inferred← citeshttps://doi.org/10.6084/m9.figshare.26597237openalex-snapshot
Additional file 4 of Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
inferred← citeshttps://doi.org/10.6084/m9.figshare.26597240openalex-snapshot
Additional file 5 of Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
inferred← citeshttps://doi.org/10.6084/m9.figshare.26597243openalex-snapshot
Additional file 6 of Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
inferred← citeshttps://doi.org/10.6084/m9.figshare.26597246openalex-snapshot
Additional file 7 of Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
inferred← citeshttps://doi.org/10.6084/m9.figshare.26597249openalex-snapshot
Additional file 8 of Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
inferred← citeshttps://doi.org/10.6084/m9.figshare.26597252openalex-snapshot
Additional file 9 of Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
inferred← citeshttps://doi.org/10.7759/cureus.66366openalex-snapshot
Secondary Immunodeficiency and Vaccine Response in Rheumatoid and Psoriatic Arthritis on Immunosuppressive Medicines
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.